Corvus Pharmaceuticals, Inc. will release interim data from its Phase 1 clinical trial of soquelitinib for patients with moderate to severe atopic dermatitis on December 18, 2024. The data will be ...
Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback